<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076943</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-092</org_study_id>
    <nct_id>NCT04076943</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia</brief_title>
  <official_title>A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and
      effective for the treatment of anemia in people receiving chemotherapy treatment for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of three periods:

        1. Screening Period up to 28 days

        2. Treatment Period of 16 weeks

        3. A Follow-up period of 4 weeks.

      A total of up to approximately 100 patients will be enrolled to receive roxadustat in an
      open-label manner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change in Hemoglobin within 16 weeks</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The primary efficacy endpoint is maximum change in hemoglobin within 16 weeks from baseline without RBC transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in hemoglobin level</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mean change in hemoglobin level from baseline to week 16 (without RBC transfusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change in hemoglobin from baseline through Week 8, 12, 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC transfusion</measure>
    <time_frame>Baseline to end of study (Week 16)</time_frame>
    <description>Number (%) of patients who had a RBC transfusion from baseline to end of study (week 16)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chemotherapy Induced Anemia</condition>
  <arm_group>
    <arm_group_label>Roxadustat (FG-4592)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat (FG-4592)</intervention_name>
    <description>Roxadustat will be dosed orally three times a week.</description>
    <arm_group_label>Roxadustat (FG-4592)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of non-myeloid malignancy

          2. Anemia caused by cancer treatment (myelosuppressive chemotherapy) defined as Hb â‰¤10.0
             g/dL at screening

          3. Planned concurrent treatment of cancer with chemotherapy for at least 8 additional
             weeks

        Exclusion Criteria:

          1. Patients with cancer receiving chemotherapy when the anticipated outcome is cure

          2. Patients who are only receiving hormonal products, biological products, cancer
             immunotherapy or radiation therapy

          3. History of leukemia

          4. Patients who have received an RBC transfusion or erythropoietic therapy within 4 weeks
             of screening

          5. Any investigational drug within 8-weeks prior to treatment with roxadustat

          6. Anemia due to other etiologies

          7. Cardiovascular risks, such as myocardial infarction, stroke, heart failure or
             thromboembolic event (e.g., deep vein thrombosis (DVT) or pulmonary embolism) within
             previous 6 months of screening

          8. Clinically significant or uncontrolled ongoing autoimmune disease (e.g., rheumatoid
             arthritis, Crohn's disease, celiac disease, etc.)

          9. Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gopal Saha</last_name>
    <phone>(415) 978-1661</phone>
    <email>gsaha@Fibrogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Bradley</last_name>
    <phone>(415) 978-1672</phone>
    <email>cbradley@Fibrogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chemotherapy induced anemia</keyword>
  <keyword>Myelosuppressive chemotherapy</keyword>
  <keyword>Non-Myeloid malignances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

